>> Genaera will begin additional mid-stage, or Phase II, trials during the current quarter and Phase III trials early next year while the earlier study is still underway. <<
Overlapping phase-2 and phase-3 trials --this is a very positive development!
This compressed timeline should significantly increase the attractiveness of the AMD program to prospective partners.
I can’t wait to see the trial-design details and the list of clinical sites.
Market Data 
Markets 
AI
